1. Ytterberg, S. R. et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N. Engl. J. Med. 386, 316–326 (2022).
2. U.S. Food and Drug Administration. FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR). https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and (2021).
3. U.S. Food and Drug Administration. Center for Drug Evaluation and Research: NDA 203,214 Tofacitinib for Rheumatoid Arthritis, Addendum to Primary Clinical Review. Edited by Department of Health and Human Services, 26 September 2012 edn. Silver Spring, MD. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203214Orig1s000Approv.pdf (2012).
4. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/results/NCT02092467 (2021).
5. Genovese, M. C. et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. Lancet Rheumatol. 2, e347–e357 (2020).